Distilbène Exposure Affects 160,000 Children Across France
Between 1948 and 1977, approximately 200,000 pregnant women in France took the synthetic estrogen drug diéthylstilbestrol, marketed as Distilbène or Stilbestrol-Borne, to prevent miscarriages and pregnancy complications. Today, those exposed range in age from 48 to 77 years old. The International Agency for Research on Cancer classifies diéthylstilbestrol as a definite human carcinogen. Among the roughly 80,000 exposed women, about one in 750 develops clear-cell adenocarcinoma, a rare cancer of the vagina or cervix. Clinical data shows that while the average age of diagnosis for this specific cancer is 24.5 years, some cases emerge after age 40. Exposed females also face high rates of uterine malformations and recurrent miscarriages, while exposed males present with testicular or urethral abnormalities.
Doctors Prescribed Medication Despite Early Warnings of Risks
Medical literature flagged early risks decades before prescriptions fully ceased. The first French case of vaginal adenocarcinoma in an exposed adolescent appeared in 1975, followed by researcher Kauffmann’s 1977 description of associated uterine abnormalities. Despite these warnings, doctors continued prescribing the medication for several years as pharmacovigilance protocols remained underdeveloped.
This exposure extended far beyond France. An estimated four million women took the drug in the United States, alongside 300,000 in the Netherlands and 8,000 in the United Kingdom.
Long-Term Health Consequences Across Generations
Decades after prescriptions stopped, the health impacts continue to emerge as adults discover rare cancers tied to their prenatal exposure. This prolonged timeline transformed how modern regulatory bodies evaluate drugs prescribed during pregnancy, leading to stricter long-term monitoring for endocrine-disrupting chemicals.
Related reading